These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32008242)

  • 1. Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements.
    Freije I; Lamouche S; Tanguay M
    Ther Innov Regul Sci; 2020 Jan; 54(1):128-138. PubMed ID: 32008242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of recently approved 505(b)(2) new drug applications (2010-2012): role of clinical pharmacology.
    Agarwal S; Qiu W; Sahajwalla C
    J Clin Pharmacol; 2014 Dec; 54(12):1330-6. PubMed ID: 24958449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway.
    Salminen WF; Wiles ME; Stevens RE
    Drug Discov Today; 2019 Jan; 24(1):46-56. PubMed ID: 30041014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
    Rising K; Bacchetti P; Bero L
    PLoS Med; 2008 Nov; 5(11):e217; discussion e217. PubMed ID: 19067477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval of modified-release products by FDA without clinical efficacy/safety studies: A retrospective survey from 2008 to 2017.
    Wang YL; Chang YT; Yang SY; Chang YW; Kuan MH; Tu CL; Hong HC; Lai IC; Gau CS; Hsu LF
    Regul Toxicol Pharmacol; 2019 Apr; 103():174-180. PubMed ID: 30711621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018.
    Heyward J; Moore TJ; Chen J; Meek K; Lurie P; Alexander GC
    Ann Intern Med; 2020 Dec; 173(12):956-963. PubMed ID: 32986486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Mid-Cycle Communications.
    Hoffman RD; Beattie SD; Camp JR; Fuhs JV
    Ther Innov Regul Sci; 2023 Jul; 57(4):689-701. PubMed ID: 37014601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019-2023) by US FDA, best practices and recommendations.
    Mitra A; Lee JB; Steinbach D; Hazra A; Krishna R
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):475-493. PubMed ID: 37925369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of quality review issues and the association with application characteristics for new drug applications in first-cycle reviews.
    Liou JS; Chang LC
    Regul Toxicol Pharmacol; 2019 Nov; 108():104448. PubMed ID: 31446093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
    Camp JR; Fuhs JV; Beattie SD; Asay RL; Hoffman RD
    Ther Innov Regul Sci; 2021 May; 55(3):568-582. PubMed ID: 33492633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From idea to market: the drug approval process.
    Lipsky MS; Sharp LK
    J Am Board Fam Pract; 2001; 14(5):362-7. PubMed ID: 11572541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.